None listed
Conditions
Interventions
Experimental group1:Atorvastatin
Experimental group2:Rosuvastatin
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers, aged >=18 years; 2. Gender is not limited, both men and women are available; 3. Body mass index is 19.0~26.0kg/m2 (including the critical value), male weight >= 50.0kg, female weight >= 45.0kg; 4. Subjects must give informed consent to this trial before the trial, and voluntarily sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Taking non-steroidal anti-inflammatory drugs or platelet inhibitors; 2. Have any history of bleeding disorders or any history of coagulation disorders; 3. Those who have any history of serious clinical diseases (circulation, respiration, digestion, urinary, blood, nerve, endocrine and metabolic systems, etc.); 4. Abnormal liver and kidney function; 5. Those who have used any known liver enzyme inducers or liver enzyme inhibitors within 30 days before the first dose; 6. Ingestion of any caffeine (such as coffee, tea, chocolate, etc.), alcohol, grapefruit (such as grapefruit juice, lemon, citrus juice, etc.) or rich in xanthine (such as sardines, beef, etc.) within 48 hours before the first dose liver, etc.) ingredients in food or drink; 7. Those who smoke more than 5 cigarettes per day within 3 months before the first drug use and those who cannot smoke during the entire trial period; 8. Those who drink heavily in the past, or drink regularly within 6 months before the test (drinking more than 14 units of alcohol per week, 1 unit = 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine); 9. Physical examination, vital signs examination, laboratory examination (blood routine, urine routine, blood biochemistry, coagulation function, etc.), 12-lead electrocardiogram with abnormal results with clinical significance and influence on the evaluation of this test; 10. Women who are pregnant, breastfeeding or planning to become pregnant during the trial, and men or women who are unwilling to take barrier contraceptive measures from 2 weeks before the first dose to 1 month after the end of the trial; 11. Contraindications of any one of clopidogrel, atorvastatin and rosuvastatin; 12. The investigators believe that they are not suitable to participate in the trial, or they cannot participate in the trial due to their own reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters;Pharmacodynamic parameters; | — |
Countries
China
Contacts
Public ContactXu Pingsheng
Xiangya Hospital, Central South University
Outcome results
None listed